News | October 02, 2024
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The company will also share results in two additional posters for deuruxolitinib
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Combined entity is better positioned to compete in increasingly competitive generics industry
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
HaystackAnalytics is engaged in the business of developing genomic analysis software
Subscribe To Our Newsletter & Stay Updated
